Board of Directors

Board of Directors

  • Timothy P. Noyes

    President and Chief Executive Officer
    Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
    • Hubert Birner, Ph.D.

      Managing Partner, TVM Capital
      Hubert Birner, Ph.D., joined TVM Capital in 2000, and is responsible for TVM Capital Life Sciences’ overall investment strategy and the fund operations in North America and Europe. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and Spepharm Holding BV (Amsterdam, The Netherlands). Before joining TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. Dr. Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilian-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. Dr. Birner holds an M.B.A. from Harvard Business School and a doctoral degree in biochemistry from Ludwig-Maximilian-University Munich, where he graduated summa cum laude. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.
    • Todd Foley

      Managing Director, MPM Capital
      Todd Foley has served as a member of our board of directors since 2012. Since 1999, Mr. Foley has been a managing director with MPM Capital, a venture capital firm, working from its Boston office. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. Mr. Foley currently serves as a member of the board of directors of Aires Pharmaceuticals, Inc., Celladon Corporation, Chiasma, Inc. and Selexys Pharmaceuticals Corporation. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
      • F. Nicholas Franano, M.D.

        Founder, Proteon Therapeutics, Inc.
        F. Nicholas Franano, M.D., has served as a member of our board of directors since 2006. Dr. Franano is currently President and Chief Executive Officer of Flow Forward Medical, Inc., and Metactive Medical, Inc., two companies developing cardiovascular medical devices, where he has served since 2014. Prior to this, Dr. Franano was founder, President and Chief Executive Officer of Novita Therapeutics, a medical device incubator company. Dr. Franano founded Proteon, and served as our Chief Executive Officer from 2001 to 2006, and after that as our Chief Scientific Officer from 2006 to 2009. Dr. Franano received an M.D. and an M.A. in biomedical research from Washington University, St. Louis, and a B.S. in cell biology from the University of Kansas. He completed a residency in diagnostic radiology and a fellowship in interventional radiology at the Johns Hopkins Hospital. Prior to founding Proteon, Dr. Franano maintained a clinical practice in interventional radiology from 2000 through 2005.
        • John G. Freund, M.D.

          Skyline Ventures
          John G. Freund, M.D., became a member of our board of directors in 2014. Dr. Freund co-founded Skyline Ventures, a venture capital firm, in 1997, where he has served as a partner since its founding. Prior to joining Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management from 1995 to 1997. In 1995, he co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994, Dr. Freund served in various positions at Acuson Corporation, now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department. Dr. Freund currently serves as a member of the board of directors of the following public companies: XenoPort, Inc., Tetraphase Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. He was on the board of MAKO Surgical Corp. from October 2008 until its acquisition in 2013. Dr. Freund also serves as a member of the board of directors of the following private companies: Advion, Inc., Collegium Pharmaceuticals, Inc., DiscoveRx Corporation, SI Bone, Inc. and Sutro Biopharma, Inc. He is a director of three mutual funds managed by Capital Research and Management. He is a member of the Advisory Board for the Harvard Business School Healthcare Initiative and is a member of the Therapeutics Advisory Council of Harvard Medical School. He received an A.B. in history from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School, where he was a Baker Scholar and won the Loeb Fellowship in Finance.
        • Dmitry Kobyzev, Ph.D.

          Investment Manager, Inbio Ventures
          Dmitry Kobyzev, Ph.D., has been a member of our board of directors since 2014. Dr. Kobyzev joined Inbio Ventures, a venture capital management company representing Pharmstandard International, S.A., in 2014 and is an Investment and Portfolio Manager. From 2010 to 2014, he served as an Investment Director of one of the top Russian life science venture capital teams at RUSNANO OJSC, which has approximately $1 billion under management. From 2005 to 2010, Dr. Kobyzev advised international private equity and Russian corporate clients within the transactions practice at PricewaterhouseCoopers Russia. Dr. Kobyzev received a Ph.D. degree in economics from Moscow State University.
          • Gregory D. Phelps

            Chairman of the Board; Partner, Red Sky Partners
            Gregory D. Phelps has been a member of our board of directors since 2008 and has served as Chairman of the Board since 2009. Mr. Phelps is an independent advisor to biotechnology and pharmaceutical companies. He was a founder and Partner of Red Sky Partners LLC, an advisory firm providing corporate development, product strategy and leadership support to life sciences companies, from 2009 to 2014. Prior to that, Mr. Phelps served as Chairman and Chief Executive Officer of RenaMed Biologics, Inc., a private biotechnology company developing a therapeutic treatment for Acute Kidney Injury, from 2004 to 2007. His previous executive management roles include Chief Executive Officer of Ardais Corporation (2002-2003), Vice Chairman and member of the executive committee of Dyax Corporation (1998-2002), Executive Vice President and Senior Vice President of Genzyme Corporation (1991-1997), Chief Executive Officer of Viagene, Inc. (1988-1990), Chief Executive Officer of ZymoGenetics, Inc. (1986-1988) and various management positions with Baxter Travenol Laboratories, Inc., now Baxter International, Inc. (1975-1986), most recently as Vice President. Mr. Phelps’ previous board directorships include Charles River School (2004-2011, board chairman 2008-2011), EPIX Pharmaceuticals Inc. (2004-2009), Ostex International Inc. (1995-2001), Atlantic Biopharmaceuticals, now Merrimack Pharmaceuticals Inc. (1998-2000), Neozyme II Corporation (1992-1996), Genzyme Transgenics Corporation, now rEVO Biologics (1993-1995) and the Hemophilia Foundation of California (1982-1984). Mr. Phelps received a B.S. in electrical engineering from Bradley University and an M.B.A. from Harvard Business School.
            • Garen Bohlin

              Consultant, Life Sciences and Healthcare Companies
              Garen Bohlin has served as a member of our board of directors since September 2014. Since May 2012, Mr. Bohlin has served as a consultant to various life sciences and healthcare companies. From January 2010 until April 2012, he served as Executive Vice President of Constellation Pharmaceuticals, a biopharmaceutical company. Prior to joining Constellation Pharmaceuticals, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, a biopharmaceutical company, from 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2008. Earlier in his career, he held multiple executive positions at Genetics Institute, a biopharmaceutical company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the board of directors of Tetraphase Pharmaceuticals and Karyopharm Therapeutics, both NASDAQ listed, and Acusphere, Inc. He also served on the board of directors for Targanta Therapeutics from 2007 to 2009, SpringLeaf Therapeutics from 2010 to 2013 and Precision Dermatology from 2012 to July 2014. Mr. Bohlin received his B.S. in accounting and finance from The University of Illinois.
              Financial Expert
            • Paul J. Hastings

              Chairman of the Board of Directors Chairman and Chief Executive Officer, OncoMed Pharmaceuticals
              Paul Hastings has served as a member of our board of directors and its chairman since October 2016. Mr. Hastings is the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastings was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007), Cerimon Pharmaceuticals and Relypsa (sold to Galenica in 2016). He is currently on the board of Pacira Pharmaceuticals, serves as Vice Chairman of Biotechnology Innovation Organization, and is also on the board of directors of the California Life Sciences Association. Mr. Hastings received a B.S. in pharmacy from the University of Rhode Island.